Comparison of anti-estrogen receptor antibodies SP1, 6F11, and 1D5 in breast cancer: Lower 1D5 sensitivity but questionable clinical implications

American Journal of Clinical Pathology

Volumn 138, Issue 5, 2012, Pages 697-702

  Bogina, G ^a   Zamboni, G ^a   Sapino, A ^a   Bortesi, L ^a   Marconi, M ^a   Lunardi, G ^a   Coati, F ^a   Massocco, A ^b   Molinaro, L ^a   Pegoraro, C ^c   Venturini, M ^a  

^a SACRO CUORE DON CALABRIA HOSPITAL   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c University of Torino ^*  (Italy)

Author keywords

1D5 antibody; 6F11 antibody; Breast cancer; Estrogen receptor; SP1 antibody

Indexed keywords

CANCER ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ANTIBODY 1D5; ESTROGEN RECEPTOR ANTIBODY 6F11; ESTROGEN RECEPTOR ANTIBODY SP1; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER CELL; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER THERAPY; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SENSITIVITY ANALYSIS;

ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; FEMALE; HUMANS; RECEPTORS, ESTROGEN; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84868142442     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPLX0QJROV2IJG     Document Type: Article

References (28)

1. Allred DC, Carlson RW, Berry DA, et al. NCCN Task Force Report: estrogen receptor and progesterone receptor testing in breast cancer by immunohistochemistry. J Natl Compr Canc Netw. 2009;7(suppl 6):S1-S21; quiz S2-3.
2. Ferrero-Pous M, Trassard M, Le Doussal V, et al. Comparison of enzyme immunoassay and immunohistochemical measurements of estrogen and progesterone receptors in breast cancer patients. Appl Immunohistochem Mol Morphol. 2001;9:267-275. (Pubitemid 32783051)
3. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28:2784-2795.
4. Regan MM, Viale G, Mastropasqua MG, et al. Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays. J Natl Cancer Inst. 2006;98:1571-1581. (Pubitemid 44680908)
5. Allred DC. Commentary: hormone receptor testing in breast cancer: a distress signal from Canada. Oncologist. 2008;13:1134-1136.
6. Rhodes A, Jasani B, Balaton AJ, et al. Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: correlation with patient age, assay sensitivity, threshold value, and mammographic screening. J Clin Pathol. 2000;53:688-696.
7. Viale G, Regan MM, Maiorano E, et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol. 2007;25:3846-3852. (Pubitemid 47477259)
8. Arihiro K, Umemura S, Kurosumi M, et al. Comparison of evaluations for hormone receptors in breast carcinoma using two manual and three automated immunohistochemical assays. Am J Clin Pathol. 2007;127:356-365. (Pubitemid 46806328)
9. Brock JE, Hornick JL, Richardson AL, et al. A comparison of estrogen receptor SP1 and 1D5 monoclonal antibodies in routine clinical use reveals similar staining results. Am J Clin Pathol. 2009;132:396-401.
10. Cheang MC, Treaba DO, Speers CH, et al. Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival. J Clin Oncol. 2006;24:5637-5644. (Pubitemid 46631303)
11. Kaplan PA, Frazier SR, Loy TS, et al. 1D5 and 6F11: An immunohistochemical comparison of two monoclonal antibodies for the evaluation of estrogen receptor status in primary breast carcinoma. Am J Clin Pathol. 2005;123:276-280. (Pubitemid 40194091)
12. Rhodes A, Sarson J, Assam EE, et al. The reliability of rabbit monoclonal antibodies in the immunohistochemical assessment of estrogen receptors, progesterone receptors, and HER2 in human breast carcinomas. Am J Clin Pathol. 2010;134:621-632.
13. Rossi S, Laurino L, Furlanetto A, et al. Rabbit monoclonal antibodies: a comparative study between a novel category of immunoreagents and the corresponding mouse monoclonal antibodies. Am J Clin Pathol. 2005;124:295-302. (Pubitemid 41060143)
14. Treaba DO, Hing AW, Tse CC, et al. Significantly improved sensitivity for ER detection in breast cancer using a new rabbit monoclonal anti-ER antibody (SP1). Mod Pathol. 2005;18:53A.
15. Vassallo J, Pinto GA, Alvarenga JM, et al. Comparison of immunoexpression of 2 antibodies for estrogen receptors (1D5 and 6F11) in breast carcinomas using different antigen retrieval and detection methods. Appl Immunohistochem Mol Morphol. 2004;12:177-182. (Pubitemid 38796461)
16. Viale G, Ghioni M, Mastropasqua MG. Traditional molecular markers and response to adjuvant endocrine or trastuzumab-based therapies. Curr Opin Oncol. 2010;22:541-546.
17. Collins LC, Botero ML, Schnitt SJ. Bimodal frequency distribution of estrogen receptor immunohistochemical staining results in breast cancer: an analysis of 825 cases. Am J Clin Pathol. 2005;123:16-20. (Pubitemid 40066167)
18. Nadji M, Gomez-Fernandez C, Ganjei-Azar P, et al. Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. Am J Clin Pathol. 2005;123:21-27. (Pubitemid 40066168)
19. Viale G, Regan MM, Maiorano E, et al. Chemoendocrine compared with endocrine adjuvant therapies for nodenegative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors- International Breast Cancer Study Group. J Clin Oncol. 2008;26:1404-1410.
20. Bezwoda WR, Esser JD, Dansey R, et al. The value of estrogen and progesterone receptor determinations in advanced breast cancer: estrogen receptor level but not progesterone receptor level correlates with response to tamoxifen. Cancer. 1991;68:867-872.
21. Badve SS, Baehner FL, Gray RP, et al. Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. J Clin Oncol. 2008;26:2473-2481.
22. Gown AM. Current issues in ER and HER2 testing by IHC in breast cancer. Mod Pathol. 2008;21(suppl 2):S8-S15. (Pubitemid 351592775)
23. Dowsett M. Estrogen receptor: methodology matters. J Clin Oncol. 2006;24:5626-5628. (Pubitemid 46631300)
24. Ibrahim M. The breast hormonal receptor module. Immunocytochemistry. 2007;6:133-138.
25. Arpino G, Weiss H, Lee AV, et al. Estrogen receptorpositive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst. 2005;97:1254-1261. (Pubitemid 41535366)
26. Millar EK, Graham PH, McNeil CM, et al. Prediction of outcome of early ER+ breast cancer is improved using a biomarker panel, which includes Ki-67 and p53. Br J Cancer. 2011;105:272-280.
27. Mohsin SK, Weiss H, Havighurst T, et al. Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Mod Pathol. 2004;17:1545-1554. (Pubitemid 39627082)
28. Raghav KP, Hernandez-Aya LF, Lei X, et al. Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancers. Cancer. 2012;118:1498-1506.